Journal of Cancer Science and Research

Journal of Cancer Science and Research
Open Access

ISSN: 2576-1447

+44 1478 350008

Mohammed sqalli Houssaini

Faculté de médecine, Université Mohammed VI des Sciences de la Santé. Casablanca, Morocco

  • Research Article   
    Metastatic hormone-sensitive prostate cancer: A Systematic Review of the Value of Current Therapies
    Author(s): Wafaa Kaikani*, Mohammed sqalli Houssaini and Khalid Hadadi

    PROSTATE cancer (PC) is the second most frequent cancer in males. Based on GLOBOCAN 2018 estimates, 1,356,176 new cases of prostate cancer and a mortality of 378,553 are expected in 20201. Despite an overall 5-year survival rate of 98.2%, mHSPC has a dismal 30% 5-year survival rate2. Metastatic hormone-sensitive prostate cancer (mHSPC) is the disease space whereby men have metastatic prostate cancer and have never received (ie. are sensitive to) androgen deprivation therapy (ADT). mHSPC previously constituted ~30% of prostate cancer cases , however, from 2004-2012 secondary to PSA testing, the estimate was ~5% of cases in USA3. Many experts in the field suggest that with decreased PSA screening over the last few years, as a result of the United States Preventative Services Task Force (USPSTF) Grade D recommendation for PSA screening (subsequently upgraded to C 4), that these estimates.. View More»

    Abstract PDF